DeepHealth to Present Recent Clinical Evidence Demonstrating the Breadth and Impact of Its AI Portfolio at RSNA 2026
Key Highlights
- ➤DeepHealth (RDNT) will present five podium talks and two posters at RSNA 2026
- ➤579,583 exams and 2,762 cancers underpin dense-breast AI detection analysis
- ➤Prostate AI combination could avoid nearly one in five biopsies at 98.4% sensitivity
- ➤Lung AI associated with 14.6% lower adjusted median reporting time
- ➤AI-supported mammography workflow improved general radiologists’ breast cancer detection
Expert Statements
Sham Sokka, Chief Operating and Technology Officer, DeepHealth
“Our connection to RadNet and our collaboration with customers and clinical partners worldwide keep real-world clinical insights at the heart of how we develop and validate AI”
Sham Sokka, Chief Operating and Technology Officer, DeepHealth
“The evidence we generate builds confidence in its use and guides how we bring clinical and operational intelligence together in everyday practice across the imaging journey and care settings.”
CHICAGO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (Nasdaq: RDNT), will present recent evidence on the clinical and workflow impacts of its AI-powered solutions across breast, thyroid, lung and prostate imaging at the Radiological Society of North America (RSNA) 2026 annual meeting.
Five podium presentations and two scientific posters will explore the role of DeepHealth AI in cancer detection, risk assessment and faster, more consistent interpretation across cancer types and imaging modalities.
Get started
Create a free account to read the full story.
